Home › Funds › MAVERICK CAPITAL LTD › RCKT
MAVERICK CAPITAL LTD position in RCKT
ROCKET PHARMACEUTICALS INC · Health Care
MAVERICK CAPITAL LTD reported holding 3,923,963 shares of RCKT (ROCKET PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$13.4M, representing 0.12% of its reported portfolio and ranking #46 among its reported holdings. MAVERICK CAPITAL LTD has disclosed RCKT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MAVERICK CAPITAL LTD's RCKT position evolved
MAVERICK CAPITAL LTD first disclosed a stake in RCKT in Q3 2023 at 5,629,970 shares (US$115.4M). The position peaked in Q4 2023 at 4,034,068 shares, worth US$120.9M. Across 12 filings, MAVERICK CAPITAL LTD increased the stake 7 time(s), trimmed it 3 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 3,923,963 shares valued at US$13.4M — an increase of 356,591 shares quarter over quarter.. Notable position changes include a 61% increase in Q2 2025 (shares rose 33% over the following quarter), a 70% trim in Q4 2025 (shares rose 2% over the following quarter), a 42% increase in Q1 2026 (shares fell 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 5.63M | $115.36M | New |
| Q4 2023 | 4.03M | $120.90M | Reduce |
| Q1 2024 | 3.89M | $104.75M | Reduce |
| Q2 2024 | 3.93M | $84.58M | Add |
| Q3 2024 | 4.12M | $76.07M | Add |
| Q4 2024 | 5.20M | $65.35M | Add |
| Q1 2025 | 5.20M | $34.68M | Hold |
| Q2 2025 | 8.36M | $20.49M | Add |
| Q3 2025 | 8.47M | $27.61M | Add |
| Q4 2025 | 2.51M | $8.82M | Reduce |
| Q1 2026 | 3.57M | $12.77M | Add |
| Q2 2026 | 3.92M | $13.42M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RCKT and 13F data
RCKT (ROCKET PHARMACEUTICALS INC) is a Health Care company. 18 other funds we track also report a position in RCKT — the largest reported positions include RTW INVESTMENTS, LP (US$60.5M), Newtyn Management, LLC (US$13.7M), Maverick Capital (US$13.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RCKT
- RTW INVESTMENTS, LP 17.69M sh · $60.49M · Q2 2026
- Newtyn Management, LLC 4.00M sh · $13.68M · Q2 2026
- Maverick Capital 3.92M sh · $13.42M · Q2 2026
- Monaco Asset Management SAM 2.48M sh · $8.48M · Q2 2026
More on MAVERICK CAPITAL LTD
FAQ
How long has MAVERICK CAPITAL LTD held RCKT?
MAVERICK CAPITAL LTD has disclosed RCKT holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is MAVERICK CAPITAL LTD's current position in RCKT?
As of Q2 2026, MAVERICK CAPITAL LTD holds 3.92M shares of RCKT (ROCKET PHARMACEUTICALS INC), valued at $13.42M, representing 0.12% of its reported portfolio and ranking #46.
Has MAVERICK CAPITAL LTD been buying or selling RCKT?
In the latest 13F filing (Q2 2026), MAVERICK CAPITAL LTD increased its position in RCKT. The position peaked in Q4 2023 at 4.03M shares.
Which other funds hold RCKT?
Other major institutional holders of RCKT include RTW INVESTMENTS, LP, Newtyn Management, LLC, Maverick Capital, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.